|
[1]
|
G. S. Murphy, J. W. Szokol, J. M. Marymont, et al., “Residual Paralysis at the Time of Tracheal Extubation,” Anesthesia & Analgesia, Vol. 100, No. 6, 2005, pp. 1840-1845.
http://dx.doi.org/10.1213/01.ANE.0000151159.55655.CB
|
|
[2]
|
S.-J. Jeong, J.-I. Han, H.-J. Baik, H. Lee, et al., “The Effect of Pyridostigmine on Bispectral Index during Recovery from Sevoflurane Anesthesia,” Korean Journal of Anesthesiology, Vol. 61, No. 6, 2011, pp. 460-464.
http://dx.doi.org/10.4097/kjae.2011.61.6.460
|
|
[3]
|
R. D. Miller, L. S. Van Nyhuis, E. I. Eger 2nd, et al., “Comparative Times to Peak Effect and Durations of Action of Neostigmine and Pyridostigmine,” Anesthesiology, Vol. 41, No. 1, 1974, pp. 27-33.
|
|
[4]
|
K. S. Kim, S. H. Lew, H. Y. Cho, et al., “Residual Paralysis Induced by Either Vecuronium or Rocuronium after Reversal with Pyridostigmine,” Anesthesia & Analgesia, Vol. 95, No. 6, 2002, pp. 1656-1660.
|
|
[5]
|
R. K. Mirakhur. “Sugammadex in Clinical Practice,” Anaesthesia, Vol. 64, Suppl. 1, 2009, pp. 45-54.
http://dx.doi.org/10.1111/j.1365-2044.2008.05870.x
|
|
[6]
|
A. F. Kopman, S. Kumar, M. M. Klewicka, et al., “The Staircase Phenomenon. Implications for Monitoring of Neuromuscular Transmission,” Anesthesiology, Vol. 95, No. 2, 2001, pp. 403-407.
|
|
[7]
|
R. S. Matteo, E. Ornstein, A. E. Schwartz, et al., “Pharmacokinetics and Pharmacodynamics of Rocuronium (Org 9426) in Elderly Surgical Patients,” Anesthesia & Analgesia, Vol. 77, No. 6, 1993, pp. 1193-1197.
|
|
[8]
|
A. Ferguson, P. Egerszegi, D. R. Bevan, et al., “Neostigmine, Pyridostigmine, and Edrophonium as Antagonists of Pancuronium,” Anesthesiology, Vol. 53. No. 5, 1980, pp. 390-394.
|
|
[9]
|
F. Donati, J. Lahoud, D. McCready, et al., “Neostigmine, Pyridostigmine and Edrophonium and Neostigmine as Antagonists of Deep Pancuronium Blockade,” Canadian Journal of Anaesthesia, Vol. 34, No. 6, 1987, pp. 589-593.
|
|
[10]
|
A. Y. Oh, S. D. Kim and C. S. Kim, “Early and Late Reversal of Rocuronium with Pyridostigmine during Sevoflurane Anaesthesia in Children,” Anaesthesia and Intensive Care, Vol. 32, No. 5, 2004, pp. 649-652.
|
|
[11]
|
S. J. Jeong, J. I. Han, H. J. Baik, et al., “The Effect of Pyridostigmine on Bispectral Index during Recovery from Sevoflurane Anesthesia,” Korean Journal of Anesthesiology, Vol. 61, No. 6, 2011, pp. 460-464.
http://dx.doi.org/10.4097/kjae.2011.61.6.460
|
|
[12]
|
A. Abrishami, J. Ho, J. Wong, et al., “Cochrane Corner: Sugammadex, a Selective Reversal Medication for Preventing Postoperative Residual Neuromuscular Blockade,” Anesthesia & Analgesia, Vol. 110, No. 4, 2010, p. 1239.
|
|
[13]
|
S. B. Groudine, R. Soto, C. Lien, et al., “A Randomized, Dose-Finding, Phase II Study of the Selective Relaxant Binding Drug, Sugammadex, Capable of Safely Reversing Profound Rocuronium-Induced Neuromuscular Block,” Anesthesia & Analgesia, Vol. 104, No. 3, 2007, pp. 555-562.
http://dx.doi.org/10.1213/01.ane.0000260135.46070.c3
|
|
[14]
|
M. Blobner, L. I. Eriksson, J. Scholz, et al., “Reversal of Rocuronium-Induced Neuromuscular Blockade with Sugammadex Compared with Neostigmine during Sevoflurane Anaesthesia: Results of a Randomised, Controlled Trial,” European Journal of Anaesthesiology, Vol. 27. No. 10, 2010, pp. 874-881.
http://dx.doi.org/10.1097/EJA.0b013e32833d56b7
|
|
[15]
|
F. Paton, M. Paulden, D. Chambers, et al., “Sugammadex Compared with Neostigmine/Glycopyrrolate for Routine Reversal of Neuromuscular Block: A Systematic Review and Economic Evaluation,” British Journal of Anaesthesia, Vol. 105, No. 5, 2010, pp. 558-567.
http://dx.doi.org/10.1093/bja/aeq269
|